Live Feeds
● LIVE Updated 1h ago · 6 sources tracked

Merck sees pivotal victory for $3B eye disease prospect

Merck's Remigromig met its primary endpoint in the pivotal Phase 2b/3 BRUNELLO study for adults with diabetic macular edema. The tri-specific agonist of the Wingless-related Integration Site (Wnt) pathway proved noninferior to ranibizumab. This result marks Merck's first success in its return to ophthalmology for a prospect with a projected $3 billion value. While the drug achieved its trial goal, reports indicate that safety concerns have emerged during the study.

🎙️

Listen to Live Briefing

Real-time synthesized voice briefing · Live Feeds Desk

⏱ ~2 min
Speed:
RSS Source map (6)
⚡ Key Developments & Real-Time Context
Text size:
  • ✓ Remigromig met the primary endpoint in the pivotal Phase 2b/3 BRUNELLO study of adults with diabetic macular edema.
  • ✓ Remigromig is a tri-specific agonist of the Wingless-related Integration Site (Wnt) pathway.
  • ✓ The drug was found to be noninferior to ranibizumab in the BRUNELLO trial.
  • ✓ The eye disease prospect has a projected value of $3 billion.
🛡️ Source Corroboration: 6 independent reporting domains (95% confidence) ⏱ Read time: ~2 min

What changed

Remigromig met its primary endpoint and demonstrated noninferiority to ranibizumab in the Phase 2b/3 BRUNELLO trial.

Live updates

  1. Merck drug Remigromig meets primary endpoint in diabetic eye disease trial

    Merck's Remigromig met its primary endpoint in the pivotal Phase 2b/3 BRUNELLO study for adults with diabetic macular edema. The tri-specific agonist of the Wingless-related Integration Site (Wnt) pathway proved noninferior to ranibizumab. This result marks Merck's first success in its return to ophthalmology for a prospect with a projected $3 billion value. While the drug achieved its trial goal, reports indicate that safety concerns have emerged during the study.

    Why it matters

    Diabetic macular edema is a complication of diabetes that affects vision. Merck is utilizing a Wnt pathway agonist to treat the condition. Success in this therapeutic area represents a strategic reentry into the ophthalmology market for the company.

    What is confirmed

    • Remigromig met the primary endpoint in the pivotal Phase 2b/3 BRUNELLO study of adults with diabetic macular edema.
    • Remigromig is a tri-specific agonist of the Wingless-related Integration Site (Wnt) pathway.
    • The drug was found to be noninferior to ranibizumab in the BRUNELLO trial.
    • The eye disease prospect has a projected value of $3 billion.

    Still unconfirmed

    • Safety concerns have cropped up regarding the Wnt drug.

    What to watch next

    • Detailed safety data release from the BRUNELLO study
    • Regulatory filing timeline for Remigromig
    Sources used for this update (6)
    1. Fierce Biotech — Merck sees pivotal victory for $3B eye disease prospect
    2. Reuters — Merck's drug for diabetes-related eye disease meets trial goal
    3. Endpoints News — Merck’s return to ophthalmology snags first success
    4. Business Wire — Merck’s Remigromig, a Tri-specific Agonist of the Wingless-related Integration Site (Wnt) Pathway, Met Primary Endpoint in the Pivotal Phase 2b/3 BRUNELLO Study of Adults with Diabetic Macular Edema
    5. Ophthalmology Times — Remigromig noninferior to ranibizumab in phase 2b/3 BRUNELLO DME trial | Eye Care Network - Modern Retina
    6. FirstWord — Merck & Co.'s Wnt drug wins in ophthalmology study, but safety concerns crop up
    confidence 95%
📊

Community Sentiment: How do you assess this situation?

Voice your perspective · Real-time aggregated sentiment from the Live Feeds community